Sangamo Therapeutics, Inc. Share Price & Technical Analysis
SGMO · $0.22 (+4.76%)
Healthcare / Biotechnology
$0.22
+4.76%
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber …
Price chart
Seasonality
Jun has 2 positive and 1 negative years (last 5 years shown)
0% return in Jun, -5% avg return in past 3 year Jun month.
5% return in 2026, 16% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 25% | -20% | -50% | -50% | 100% | 0% | – | – | – | – | – | – | 5% |
| 25 | 20% | -17% | -30% | 14% | -37% | 0% | 0% | 0% | 40% | -14% | -17% | 0% | -41% |
| 24 | 0% | 140% | -36% | -29% | 20% | -33% | 100% | 13% | 13% | 89% | 28% | -57% | 247% |
| 23 | 13% | -14% | -40% | -17% | -21% | 18% | 0% | -23% | -40% | 0% | -33% | 0% | -158% |
| 22 | -21% | -5% | 0% | -28% | -12% | 11% | 2% | 26% | -8% | -12% | -18% | -16% | -80% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Downtrend · Uptrend
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; giroctocogene fitelparvovec, a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male with moderately severe or severe hemophilia A. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. ALS and Frontotemporal Lobar Degeneration; Takeda Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$83.27M
P/E ratio
—
52W high
$0.77
52W low
$0.10
Volume
6,55,831
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Sangamo Therapeutics, Inc. share price today?
- Sangamo Therapeutics, Inc. (SGMO) last traded around $0.22 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SGMO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SGMO. Download the app for real-time alerts.
- How can I analyze Sangamo Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.